Literature DB >> 23557420

Adjuvant immunotherapies as a novel approach to bacterial infections.

Elisa T Helbig1, Bastian Opitz, Leif E Sander.   

Abstract

The rapid emergence of multidrug-resistant pathogens, especially Gram-negative bacteria and mycobacteria, represents one of the major medical challenges of the 21st century. The gradual loss of effective classical antibiotics for many bacterial pathogens, combined with an increasing population density and mobility, urgently calls for the development of novel treatments. Here, we discuss the potential of adjuvant immunotherapies to selectively stimulate protective immune responses as a treatment option for bacterial infections. In order to elicit appropriate immune responses and to avoid unwanted inflammatory tissue damage, it is essential to identify ligands and receptor pathways that specifically control protective responses at the site of infection. We summarize existing data and discuss suitable candidate targets for future immunotherapies of infectious diseases.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23557420     DOI: 10.2217/imt.13.17

Source DB:  PubMed          Journal:  Immunotherapy        ISSN: 1750-743X            Impact factor:   4.196


  5 in total

Review 1.  Mycobacterium Tuberculosis and Interactions with the Host Immune System: Opportunities for Nanoparticle Based Immunotherapeutics and Vaccines.

Authors:  Raymonde B Bekale; Su-Mari Du Plessis; Nai-Jen Hsu; Jyoti R Sharma; Samantha L Sampson; Muazzam Jacobs; Mervin Meyer; Gene D Morse; Admire Dube
Journal:  Pharm Res       Date:  2018-11-08       Impact factor: 4.200

2.  ESAT-6-dependent cytosolic pattern recognition drives noncognate tuberculosis control in vivo.

Authors:  Andreas Kupz; Ulrike Zedler; Manuela Stäber; Carolina Perdomo; Anca Dorhoi; Roland Brosch; Stefan H E Kaufmann
Journal:  J Clin Invest       Date:  2016-04-25       Impact factor: 14.808

3.  Pyrimidine synthesis inhibition enhances cutaneous defenses against antibiotic resistant bacteria through activation of NOD2 signaling.

Authors:  Samreen Jatana; Craig R Homer; Maria Madajka; András K Ponti; Amrita Kabi; Francis Papay; Christine McDonald
Journal:  Sci Rep       Date:  2018-06-07       Impact factor: 4.379

Review 4.  Development and Research Progress of Anti-Drug Resistant Bacteria Drugs.

Authors:  Xiangyi Cui; Yuhong Lü; Changwu Yue
Journal:  Infect Drug Resist       Date:  2021-12-21       Impact factor: 4.003

5.  Treatment of mice with S4B6 IL-2 complex prevents lethal toxoplasmosis via IL-12- and IL-18-dependent interferon-gamma production by non-CD4 immune cells.

Authors:  Andreas Kupz; Saparna Pai; Paul R Giacomin; Jennifer A Whan; Robert A Walker; Pierre-Mehdi Hammoudi; Nicholas C Smith; Catherine M Miller
Journal:  Sci Rep       Date:  2020-08-04       Impact factor: 4.379

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.